FORMICA RUFA 2CH-200CH Granule Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

formica rufa 2ch-200ch granule

boiron, messimy array - 51020 formica rufa - dilutio homeopathica - granule - 2ch-200ch - homeopatika (ČeskÁ atc skupina)

POLAPIX 2,5MG Potahovaná tableta Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

polapix 2,5mg potahovaná tableta

zaklady farmaceutyczne polpharma sa, starogard gdański array - 17381 apixaban - potahovaná tableta - 2,5mg - apixaban

POLAPIX 5MG Potahovaná tableta Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

polapix 5mg potahovaná tableta

zaklady farmaceutyczne polpharma sa, starogard gdański array - 17381 apixaban - potahovaná tableta - 5mg - apixaban

Ionsys Evropská unie - čeština - EMA (European Medicines Agency)

ionsys

incline therapeutics europe ltd - fentanyl-hydrochloridu - bolest, pooperační - analgetika - přípravek ionsys je určen k léčbě akutní mírné až těžké pooperační bolesti u dospělých pacientů.

Formicpro 68,2 g Proužek do úlu Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

formicpro 68,2 g proužek do úlu

nod apiary ireland ltd. - kyselina mravenčí - proužek do úlu - organické kyseliny - včelstva včely medonosné(apis mellifica)

Aubagio Evropská unie - čeština - EMA (European Medicines Agency)

aubagio

sanofi winthrop industrie - teriflunomid - roztroušená skleróza - selektivní imunosupresiva - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Teriflunomide Mylan Evropská unie - čeština - EMA (European Medicines Agency)

teriflunomide mylan

mylan pharmaceuticals limited - teriflunomid - roztroušená skleróza, relaps-remitentní - imunosupresiva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Wegovy Evropská unie - čeština - EMA (European Medicines Agency)

wegovy

novo nordisk a/s - semaglutid - obesity; overweight - preparáty proti obezitě, diety - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to.

Tysabri Evropská unie - čeština - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalizumab - roztroušená skleróza - selektivní imunosupresiva - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 a 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Tyruko Evropská unie - čeština - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 a 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.